News

TB R&D Weekly Update: Podcast Interview with Anne Lenaerts

[wpaudio url=”/blog/media/podcasts/Anne_Lenaerts_Interview_edited-norm.mp3″ text=”Anne Lenaerts Interview” dl=”0″]

Listen to Anne Lenaerts Podcast


Summary: Dr. Anne Lenaerts is an associate professor at Colorado State University”s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology and Pathology. The WGND had the opportunity to talk with Dr. Lenaerts on a recent article published ahead of print in the Antimicrobial Agents and Chemotherapy journal in December 2010. In the interview, Dr. Lenaerts provides an overview of her present research and the article, key recommendations for use of mouse models for testing TB drugs and the issue of relapse studies.

Additional TB R&D News:

REVIEW: The challenge of new drug discovery for tuberculosis

Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies

Progress in tuberculosis vaccine research

Race against time to develop new antibiotics

S. Korean Biotech Company Decodes Antibiotic Resistant Superbug form

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...